Research Study to Compare a New Medicine Fast-acting Insulin Aspart to Another Medicine Insulin Aspart in Chinese People With Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 331 participants.
Also called NCT04588259
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 331 participants
- Sponsor
- Registry
-
NCT04588259
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Hong Kong SAR China
- Registry status
- Completed
Technical summary
Registry record NCT04588259. Randomized; quadruple masking; primary purpose treatment. Start 2020-10-09 (actual); primary completion 2022-07-05 (actual). Results posted on 2024-03-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
- Condition
- Diabetes Mellitus, Type 1
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Faster aspart
- Intervention (Drug)
- Insulin aspart
- Intervention (Drug)
- Insulin degludec
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04588259- Content hash
2bc0ba240a4cca66c62448a973d897fbce2d70f5e1ea4f00b909a9f9a2b0f833